Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Unknown 1

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 3Colorectal Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Fluorouracil 29Leucovorin 26Oxaliplatin 25Capecitabine 16Irinotecan 14Cetuximab 10Bevacizumab 9Radiotherapy 8Panitumumab 5Folfox protocol 5Surgical Procedures, Operative 3Levamisole 3Celecoxib 3tremelimumab 2neratinib 2napabucasin 2durvalumab 2cediranib 2aflibercept 2X-Rays 2Tegafur 2Radiofrequency Ablation 2Psychiatric Rehabilitation 2Preoperative Exercise 2Octreotide 2Mitomycin 2Interviews as Topic 2Immunoglobulin G 2Folic Acid 2Floxuridine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Colorectal Neoplasms × neratinib × Clear all
NCT03457896 2022-03-31

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

NSABP Foundation Inc

Phase 2 Unknown
35 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT01960023 2021-10-27

Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer

NSABP Foundation Inc

Phase 1/2 Withdrawn
Gastrointestinal

Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡